27.85
-0.25(-0.89%)
Currency In USD
Address
11-12 St. James's Square
London, SW1Y 4LB
United Kingdom of Great Britain and Northern Ireland
Phone
44 2074 003 347
Website
Sector
Healthcare
Industry
Biotechnology
Employees
908
First IPO Date
December 08, 2020
| Name | Title | Pay | Year Born |
| Matthew Gline | Chief Executive Officer & Director | 5.72M | 1984 |
| Eric Venker | President & Chief Executive Officer of Immunovant | 6.67M | 1987 |
| Jennifer Humes | Chief Accounting Officer | 324,640 | 1981 |
| Richard Pulik | Chief Financial Officer | 1.55M | 1980 |
| Mayukh Sukhatme | President, Chief Investment Officer & Director | 81.64M | 1976 |
| Frank Torti | President & Vant Chair | 0 | 1979 |
| Huafeng Xu | Chief Technology Officer | 0 | N/A |
| Ian Rosenblum | Chief Information Officer | 0 | N/A |
| Josh Chen | General Counsel | 0 | N/A |
| Kelly Graff | Head of People | 0 | N/A |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.